MARKET

LIXT

LIXT

Lixte Biotechnology Hldgs Inc
NASDAQ
2.930
-0.120
-3.93%
After Hours: 2.930 0 0.00% 16:10 04/13 EDT
OPEN
2.960
PREV CLOSE
3.050
HIGH
3.080
LOW
2.930
VOLUME
31.11K
TURNOVER
--
52 WEEK HIGH
6.26
52 WEEK LOW
0.6400
MARKET CAP
34.04M
P/E (TTM)
-2.3334
1D
5D
1M
3M
1Y
5Y
1D
LIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference
TipRanks · 11h ago
Lixte reports favorable interim results for LB-100 plus dostarlimab ovarian cancer trial
PUBT · 16h ago
Lixte Biotechnology presents preliminary LB100 results
TipRanks · 16h ago
FAVORABLE RESULTS OF OVARIAN CANCER STUDY PRESENTED AT ANNUAL SOCIETY OF GYNECOLOGICAL CARE CONFERENCE
Reuters · 16h ago
Weekly Report: what happened at LIXT last week (0406-0410)?
Weekly Report · 18h ago
Lixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships
TipRanks · 3d ago
Weekly Report: what happened at LIXT last week (0330-0403)?
Weekly Report · 04/06 09:25
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year
TipRanks · 04/02 15:00
More
About LIXT
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. It is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue. Its subsidiary, Liora Technologies Europe Ltd., offers electronically controlled proton therapy systems for treating tumors in various types of cancers.

Webull offers Lixte Biotechnology Holdings Inc stock information, including NASDAQ: LIXT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIXT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LIXT stock methods without spending real money on the virtual paper trading platform.